Plasma amitriptyline level after acute administration, and driving performance in healthy volunteers

Background Depression is characterised by negative views of the self. Antidepressant treatment may remediate negative self-schema through increasing processing of positive information about the self. Changes in affective processing during social interactions may increase expression of prosocial behaviours, improving interpersonal communications. Aims To examine whether acute administration of citalopram is associated with an increase in positive affective learning biases about the self and prosocial behaviour. Method Healthy volunteers (n = 41) were randomised to either an acute 20 mg dose of citalopram or matched placebo in a between-subjects double-blind design. Participants completed computer-based cognitive tasks designed to measure referential affective processing, social cognition and expression of prosocial behaviours. Results Participants administered citalopram made more cooperative choices than those administered placebo in a prisoner's dilemma task (β = 20%, 95% CI: 2%, 37%). Exploratory analyses indicated that participants administered citalopram showed a positive bias when learning social evaluations about a friend (β = 4.06, 95% CI: 0.88, 7.24), but not about the self or a stranger. Similarly, exploratory analyses found evidence of increased recall of positive words and reduced recall of negative words about others (β = 2.41, 95% CI: 0.89, 3.93), but not the self, in the citalopram group. Conclusions Participants administered citalopram showed greater prosocial behaviours, increased positive recall and increased positive learning of social evaluations towards others. The increase in positive affective bias and prosocial behaviours towards others may, at least partially, be a mechanism of antidepressant effect. However, we found no evidence that citalopram influenced self-referential processing.

Download Full-text

P.1.e.019 Acute administration of the anti-psychotic sulpiride modulates the neural response to chocolate in healthy volunteers

European Neuropsychopharmacology ◽

10.1016/s0924-977x(10)70398-9 ◽

2010 ◽

Vol 20 ◽

pp. S299

Author(s):

C. McCabe ◽

A. Huber ◽

C.J. Harmer ◽

P.J. Cowen

Keyword(s):

Healthy Volunteers ◽

Neural Response ◽

Acute Administration ◽

Anti Psychotic

Download Full-text

A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers

Hormone and Metabolic Research ◽

10.1055/a-1498-7098 ◽

2021 ◽

Vol 53 (06) ◽

pp. 402-407

Author(s):

Tuuli Sedman ◽

Vallo Volke ◽

Keiu Heinla ◽

Eero Vasar

Keyword(s):

Healthy Volunteers ◽

Ambulatory Setting ◽

Controlled Study ◽

Acute Administration ◽

Open Label ◽

Glucose Levels ◽

Adrenal Axis ◽

Blood Glucose Levels ◽

Glucagon Like Peptide 1 ◽

Pituitary Adrenal Axis

AbstractGlucagon-like peptide 1 receptor agonists (GLP-1 RAs) are antidiabetic drugs with effects beyond antihyperglycemic action. The aim of the study was to examine whether a single dose of exenatide could be used as a stimulation test for the pituitary-adrenal axis. We carried out a single-group, open-label pilot clinical trial in an ambulatory setting. Ten healthy volunteers of both sexes with body weight>65 kg and age between 18–50 years were recruited. After fasting for 12 hours the subjects received 10 μg of exenatide solution subcutaneously. Blood samples were taken before the administration of exenatide and up to 150 minutes thereafter. The primary outcome was the maximal level of cortisol after the administration of exenatide. Single administration of exenatide 10 μg resulted in a modest increase in ACTH and cortisol levels, as compared to untreated values, and a decrease in blood glucose levels. Remarkably, a robust suppression of both renin and aldosterone levels occurred. We showed that acute administration of exenatide in a full therapeutic dose modestly stimulates the hypothalamic-pituitary-adrenal axis but inhibits the renin-aldosterone system. Further research is warranted to confirm this finding in the placebo-controlled study.

Download Full-text

Behavioral, cardiovascular and neuroendocrine indices of cholecystokinin tetrapeptide induced panic symptoms in healthy volunteers following acute administration of a tryptophan deficient diet.

10.22215/etd/1994-02868 ◽

1994 ◽

Author(s):

Diana Koszycki

Keyword(s):

Healthy Volunteers ◽

Acute Administration ◽

Deficient Diet ◽

Panic Symptoms

Download Full-text

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers

SLEEP ◽

10.5665/sleep.5168 ◽

2015 ◽

Vol 38 (11) ◽

pp. 1803-1813 ◽

Cited By ~ 31

Author(s):

Annemiek Vermeeren ◽

Hong Sun ◽

Eric F.P.M. Vuurman ◽

Stefan Jongen ◽

Cees J. Van Leeuwen ◽

...

Keyword(s):

Healthy Volunteers ◽

Driving Performance ◽

The Road ◽

On The Road

Download Full-text

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

SLEEP ◽

10.1093/sleep/zsy260 ◽

2018 ◽

Vol 42 (4) ◽

Cited By ~ 16

Author(s):

Annemiek Vermeeren ◽

Stefan Jongen ◽

Patricia Murphy ◽

Margaret Moline ◽

Gleb Filippov ◽

...

Keyword(s):

Healthy Volunteers ◽

Lateral Position ◽

Driving Performance ◽

Symmetry Analysis ◽

Double Blind ◽

Clinical Trial Registration ◽

Previous Night ◽

The Road ◽

On The Road ◽

Mean Differences

Abstract Study Objectives To assess potential effects of lemborexant on next-morning driving performance in adult and elderly healthy volunteers. Methods Randomized, double-blind, double-dummy, placebo and active-controlled, four period incomplete crossover study in 48 healthy volunteers (22 females), 23–78 years old. Participants were treated at bedtime for eight consecutive nights with two of three dose levels of lemborexant (2.5, 5, or 10 mg), zopiclone 7.5 mg (on the first and last night with placebo on intervening nights), or placebo. Driving performance was assessed in the morning on days 2 and 9 using a standardized highway driving test in normal traffic, measuring standard deviation of lateral position (SDLP). Drug–placebo differences in SDLP >2.4 cm were considered to reflect clinically meaningful driving impairment. Results Mean drug–placebo differences in SDLP following lemborexant 2.5, 5, and 10 mg on days 2 and 9 were 0.74 cm or less. The upper bound of the 95% confidence intervals (CIs) for lemborexant treatment groups were all below 2.4 cm and the 95% CIs included zero, indicating that the effects were neither clinically meaningful nor statistically significant. Symmetry analysis further supported the lack of clinically meaningful impairment with lemborexant. Conclusions When assessed starting ~9 h after lemborexant administration at bedtime the previous night, there was no statistically significant or clinically meaningful effect on driving performance in healthy adults and elderly, as assessed by either mean differences in SDLP relative to placebo or symmetry analysis. In this study, lemborexant at doses up to 10 mg was well-tolerated. Clinical Trial Registration clinicaltrials.gov, NCT02583451. https://clinicaltrials.gov/ct2/show/NCT02583451.

Download Full-text